Ossiam Purchases 470,962 Shares of Merck & Co., Inc. (NYSE:MRK)

Ossiam raised its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 581.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 552,025 shares of the company’s stock after purchasing an additional 470,962 shares during the period. Merck & Co., Inc. makes up about 1.0% of Ossiam’s investment portfolio, making the stock its 25th largest holding. Ossiam’s holdings in Merck & Co., Inc. were worth $60,182,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC purchased a new position in Merck & Co., Inc. in the 4th quarter worth about $27,000. Burkett Financial Services LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Bare Financial Services Inc purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $30,000. Finally, RIA Advisory Group LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $30,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock traded up $0.15 during mid-day trading on Friday, hitting $130.67. The stock had a trading volume of 4,945,599 shares, compared to its average volume of 7,277,381. Merck & Co., Inc. has a one year low of $99.14 and a one year high of $133.10. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $330.96 billion, a P/E ratio of 145.19, a P/E/G ratio of 2.52 and a beta of 0.39. The firm’s 50 day moving average is $128.51 and its 200 day moving average is $121.47.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.40 earnings per share. On average, sell-side analysts forecast that Merck & Co., Inc. will post 8.64 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 342.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday. Societe Generale downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target for the company. in a research note on Monday, March 11th. Truist Financial increased their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Get Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.